SGO Annual Meeting on Women's Cancer

Checkpoint Inhibitors Induce Response, Higher Rates of Side Effects

March 26th 2018, 5:17pm

Article

“There has been a rapid expansion in the use of checkpoint inhibition in many solid tumor types,” lead author Emily Hinchcliff, M.D.

Four Individuals Named Ovarian Cancer Heroes at Inaugural Event

March 24th 2018, 4:29pm

Article

At the inaugural Ovarian Cancer Heroes gala, held in New Orleans ahead of the 49th Society of Gynecologic Oncology Annual Meeting on Women’s Cancers, four individuals — a physician, nurse navigator and two patient-turned-advocates — were awarded for the contributions they have made to increase awareness and advance research and education for ovarian cancer.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017, 9:19pm

Article

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017, 8:20pm

Article

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

March 15th 2017, 6:41pm

Video

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

March 15th 2017, 4:52pm

Article

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15th 2017, 12:37am

Video

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017, 10:32pm

Article

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Declining Concern about HPV Vaccine and Sexual Activity

March 13th 2017, 11:53pm

Article

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert

March 13th 2017, 10:26pm

Article

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.